POXEL Stock Overview
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Poxel S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.77 |
| 52 Week High | €0.95 |
| 52 Week Low | €0.30 |
| Beta | 1.57 |
| 1 Month Change | 48.08% |
| 3 Month Change | 67.03% |
| 1 Year Change | 12.41% |
| 3 Year Change | -88.04% |
| 5 Year Change | -89.14% |
| Change since IPO | -89.29% |
Recent News & Updates
Recent updates
Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%
Mar 27
Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?
May 07How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 16How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?
Nov 17
Shareholder Returns
| POXEL | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 19.6% | 3.1% | 2.2% |
| 1Y | 12.4% | -9.1% | 3.2% |
Return vs Industry: POXEL exceeded the French Biotechs industry which returned -13% over the past year.
Return vs Market: POXEL exceeded the French Market which returned 1.3% over the past year.
Price Volatility
| POXEL volatility | |
|---|---|
| POXEL Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: POXEL's share price has been volatile over the past 3 months.
Volatility Over Time: POXEL's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 15 | Thomas Kuhn | www.poxelpharma.com |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications.
Poxel S.A. Fundamentals Summary
| POXEL fundamental statistics | |
|---|---|
| Market cap | €29.84m |
| Earnings (TTM) | -€44.24m |
| Revenue (TTM) | €1.55m |
19.3x
P/S Ratio-0.7x
P/E RatioIs POXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POXEL income statement (TTM) | |
|---|---|
| Revenue | €1.55m |
| Cost of Revenue | €1.54m |
| Gross Profit | €2.00k |
| Other Expenses | €44.24m |
| Earnings | -€44.24m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 0.13% |
| Net Profit Margin | -2,861.58% |
| Debt/Equity Ratio | -112.1% |
How did POXEL perform over the long term?
See historical performance and comparison